Brainstrorm Cell Therpay

BrainStorm Cell Therapeutics, Inc.
OTC BB: BCLI

Executive Summary
October 2007

Contact information:

Chaim Levinson
Investor Relations Director
[email protected]
Mobile: 972-545-633683

BrainStorm’s Value Proposition
BrainStorm is an early stage biotechnology company focused on developing innovative adult stem cell therapies for highly debilitating neurodegenerative disorders, such as Parkinson’s disease, Amyotrophic Lateral Sclerosis (also known as Lou Gehrig's disease), Multiple Sclerosis and spinal cord injury. Addressing the core pathology underlying neurodegenerative diseases rather than treating their symptoms, NurOwn™ treated patients are expected to enjoy a rapid recovery and much enhanced quality of life.
BrainStorm’s NurOwn™ therapy will provide—after full commercialization—compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By treating debilitating diseases, BrainStorm will enable healthcare institutions and society at large to realized massive savings in treatment and care costs.

This executive summary contains forward-looking statements that address a variety of subjects including, for example, the expected development and growth of markets in which BrainStorm Cell Therapeutics operates, expected future advances and expansion, expected revenue growth and opportunities, expected cash resources and equity and/or debt financings, the further execution of BrainStorm’s strategic business plan and growth of its businesses. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: BrainStorm’s success, includi ...
Word (s) : 2639
Pages (s) : 11
View (s) : 914
Rank : 0
   
Report this paper
Please login to view the full paper

Recent Topics

New Entries

Most Recent Request

Join Now